Scholarlink

Purpose <p>Transient improvement of aphasia, motor impairment, and disorders of consciousness after the use of zolpidem, a sedative, has been reported in several movement disorders and hyporesponsive syndromes. Here, we present a patient with Primary Familial Brain Calcification (PFBC), a rare neurodegenerative disease characterized by basal ganglia calcification, who experienced a transient improvement in speech following zolpidem administration.</p> Methods <p>Serendipitously, a 40-year-old female with PFBC and severe dysarthria experienced transient amelioration of dysarthria after treatment with zolpidem, which was prescribed for insomnia. We carried out a comprehensive clinical assessment before and three hours after administration of zolpidem tartrate 10&#xa0;mg, including standardized evaluations of speech, aphasia, motor function, and patient-perceived difficulties.</p> Results <p>A transient improvement in speech was confirmed after zolpidem intake. However, notable side effects occurred, including worsening of fine motor control, coordination, postural stability, and bradykinesia.</p> Conclusions <p>This case suggests that zolpidem can influence PFBC related neurological symptoms, identifying the facilitation of internal globus pallidus inhibition as a new therapeutic target. Its use in individual patients warrants the weighing of positive and negative clinical effects, patients’ personal preferences, and wearing-off which invariable occurs after repeated use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short-term amelioration of dysarthria after Zolpidem intake in a patient with primary familial brain calcification: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月15日

查看全文
  • Birgitta M.G. Snijders,
  • Willemijn S. van Erp,
  • Merlijn Storm,
  • Johanna A. Netjes,
  • Evelien van Valen,
  • Susan Bakker,
  • Mike J.L. Peters,
  • Pim A. de Jong,
  • Marielle H. Emmelot-Vonk,
  • Huiberdina L. Koek

摘要

Purpose

Transient improvement of aphasia, motor impairment, and disorders of consciousness after the use of zolpidem, a sedative, has been reported in several movement disorders and hyporesponsive syndromes. Here, we present a patient with Primary Familial Brain Calcification (PFBC), a rare neurodegenerative disease characterized by basal ganglia calcification, who experienced a transient improvement in speech following zolpidem administration.

Methods

Serendipitously, a 40-year-old female with PFBC and severe dysarthria experienced transient amelioration of dysarthria after treatment with zolpidem, which was prescribed for insomnia. We carried out a comprehensive clinical assessment before and three hours after administration of zolpidem tartrate 10 mg, including standardized evaluations of speech, aphasia, motor function, and patient-perceived difficulties.

Results

A transient improvement in speech was confirmed after zolpidem intake. However, notable side effects occurred, including worsening of fine motor control, coordination, postural stability, and bradykinesia.

Conclusions

This case suggests that zolpidem can influence PFBC related neurological symptoms, identifying the facilitation of internal globus pallidus inhibition as a new therapeutic target. Its use in individual patients warrants the weighing of positive and negative clinical effects, patients’ personal preferences, and wearing-off which invariable occurs after repeated use.